|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 16/09 | Vericel Corporation Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 02:35 PM | |
| 31/07 | Truist Raises Price Target on Vericel to $58 From $54, Keeps Buy Rating | MT |
| Market Cap | 207.95Cr 183.52Cr 173.63Cr 157.47Cr 295.22Cr 20TCr 298.14Cr 2.08TCr 802.79Cr 10TCr 780.85Cr 763.86Cr 33TCr | P/E 2026 * |
73.5x | P/E 2027 * | 46.1x |
|---|---|---|---|---|---|
| Enterprise Value | 207.95Cr 183.52Cr 173.63Cr 157.47Cr 295.22Cr 20TCr 298.14Cr 2.08TCr 802.79Cr 10TCr 780.85Cr 763.86Cr 33TCr | EV / Sales 2026 * |
6.18x | EV / Sales 2027 * | 5.29x |
| Free-Float |
98.81% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Aastrom Biosciences Inc
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 01/03/2013 | |
Joseph Mara
DFI | Director of Finance/CFO | 51 | 25/01/2021 |
| Chief Tech/Sci/R&D Officer | - | 01/01/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Alan Rubino
BRD | Director/Board Member | 71 | 28/09/2005 |
Robert Zerbe
CHM | Chairman | 75 | 05/10/2012 |
Heidi Hagen
BRD | Director/Board Member | 57 | 23/08/2013 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.20% | +3.11% | +55.55% | +120.48% | 1,05600Cr | |
| -0.05% | -1.05% | +43.64% | +71.66% | 64TCr | |
| +0.16% | -0.69% | +13.70% | +77.57% | 47TCr | |
| -1.09% | -0.36% | +75.80% | +43.88% | 37TCr | |
| -0.19% | -3.96% | +34.21% | +40.62% | 34TCr | |
| -0.30% | +2.36% | +20.24% | +28.93% | 28TCr | |
| -1.01% | -1.13% | +9.91% | +12.24% | 25TCr | |
| -0.31% | +4.01% | +49.67% | +58.60% | 23TCr | |
| -0.84% | -0.60% | +35.55% | +103.05% | 19TCr | |
| Average | -0.44% | +0.12% | +37.58% | +61.89% | 42.4TCr | |
| Weighted average by Cap. | -0.37% | +0.30% | +41.59% | +74.20% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 34Cr 30Cr 28Cr 25Cr 48Cr 3.23TCr 48Cr 336.79Cr 129.8Cr 1.65TCr 126.25Cr 123.5Cr 5.3TCr | 39Cr 35Cr 33Cr 30Cr 56Cr 3.77TCr 56Cr 393.57Cr 151.68Cr 1.93TCr 147.54Cr 144.33Cr 6.2TCr |
| Net income | 2.93Cr 2.58Cr 2.45Cr 2.22Cr 4.16Cr 281.05Cr 4.2Cr 29Cr 11Cr 143.52Cr 11Cr 11Cr 461.84Cr | 4.73Cr 4.17Cr 3.95Cr 3.58Cr 6.71Cr 453.76Cr 6.78Cr 47Cr 18Cr 231.71Cr 18Cr 17Cr 745.66Cr |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
